GlaxoSmithKline PLC Director/PDMR Shareholding (4038W)
April 16 2019 - 12:14PM
UK Regulatory
TIDMGSK
RNS Number : 4038W
GlaxoSmithKline PLC
16 April 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================
a) Name Ms E N Walmsley
=== ======================== ===========================================
b) Position/status Chief Executive Officer
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 April 2019.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 1856.065
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-04-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================
a) Name Mr R G Connor
=== ======================== ===========================================
b) Position/status President, Global Vaccines
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 April 2019.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 835.687
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-04-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================
a) Name Ms D Conrad
=== ======================== ===========================================
b) Position/status SVP, Human Resources
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 April 2019.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 9.069
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-04-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them ('PCA')
======================================================================
a) Name Mr S P Dingemans
=== ========================= ===========================================
b) Position/status Executive Director
=== ========================= ===========================================
c) Initial notification/ Initial notification
amendment
=== ========================= ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ======================================================================
a) Name GlaxoSmithKline plc
=== ========================= ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ========================= ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ======================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ========================= ===========================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 April 2019.
=== ========================= ===========================================
c) Price(s) and volume(s) Price(s) Volume(s)
----------
GBP15.5009 0.001
----------
=== ========================= ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ========================= ===========================================
e) Date of the transaction 2019-04-15
=== ========================= ===========================================
f) Place of the transaction London Stock Exchange (XLON)
=== ========================= ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=========================================================================
a) Name Mr J Ford
=== ======================== ===============================================
b) Position/status SVP & General Counsel
=== ======================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =========================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =========================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
=== ======================== ===============================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 11
April 2019.
=== ======================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.8259 0.002
----------
=== ======================== ===============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===============================================
e) Date of the transaction 2019-04-12
=== ======================== ===============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=============================================================================
a) Name Mr J Ford
=== ======================= ====================================================
b) Position/status SVP & General Counsel
=== ======================= ====================================================
c) Initial notification/ Initial notification
amendment
=== ======================= ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =============================================================================
a) Name GlaxoSmithKline plc
=== ======================= ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ======================= ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =============================================================================
a) Description Ordinary shares of 25 pence each ('Ordinary
of the financial Shares')
instrument ISIN: GB0009252882
=== ======================= ====================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to shareholders
on 11 April 2019.
=== ======================= ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 0.000034
----------
=== ======================= ====================================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================= ====================================================
e) Date of the 2019-04-15
transaction
=== ======================= ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================= ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=======================================================================
a) Name Mr N Hirons
=== ====================== ===============================================
b) Position/status SVP, Global Ethics & Compliance
=== ====================== ===============================================
c) Initial notification/ Initial notification
amendment
=== ====================== ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =======================================================================
a) Name GlaxoSmithKline plc
=== ====================== ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =======================================================================
a) Description American Depositary Shares ('ADSs')
of the financial ISIN: US37733W1053
instrument
=== ====================== ===============================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 11
April 2019
=== ====================== ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.8259 22.812
----------
=== ====================== ===============================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ===============================================
e) Date of the 2019-04-12
transaction
=== ====================== ===============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ====================== ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================
a) Name Mr N Hirons
=== ======================== ===========================================
b) Position/status SVP, Global Ethics & Compliance
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 April 2019.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 839.365
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-04-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
============================================================================
a) Name Mr D Jackson
=== ====================== ====================================================
b) Position/status PCA of Ms S Jackson (SVP, Global Communications
and CEO Office)
=== ====================== ====================================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ============================================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================================
a) Description Ordinary shares of 25 pence each ('Ordinary
of the financial Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to shareholders
on 11 April 2019.
=== ====================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 73.793
----------
=== ====================== ====================================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ====================================================
e) Date of the 2019-04-15
transaction
=== ====================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
============================================================================
a) Name Mrs S Jackson
=== ====================== ====================================================
b) Position/status SVP, Global Communications and CEO Office
=== ====================== ====================================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ============================================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================================
a) Description Ordinary shares of 25 pence each ('Ordinary
of the financial Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to shareholders
on 11 April 2019.
=== ====================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 112.492
----------
=== ====================== ====================================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ====================================================
e) Date of the 2019-04-15
transaction
=== ====================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
========================================================================
a) Name Mr B McNamara
=== ======================= ===============================================
b) Position/status CEO, GSK Consumer Healthcare
=== ======================= ===============================================
c) Initial notification/ Initial notification
amendment
=== ======================= ===============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ========================================================================
a) Name GlaxoSmithKline plc
=== ======================= ===============================================
b) LEI 5493000HZTVUYLO1D793
=== ======================= ===============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ========================================================================
a) Description American Depositary Shares ('ADSs')
of the financial ISIN: US37733W1053
instrument
=== ======================= ===============================================
b) Nature of the Acquisition of ADSs following the re-investment
transaction of dividends paid to shareholders on 11
April 2019
=== ======================= ===============================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
$ 40.8259 947.143
----------
=== ======================= ===============================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================= ===============================================
e) Date of the 2019-04-12
transaction
=== ======================= ===============================================
f) Place of the New York Stock Exchange (XNYS)
transaction
=== ======================= ===============================================
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================
a) Name Mr D Redfern
=== ======================== ===========================================
b) Position/status Chief Strategy Officer
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 April 2019.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 3072.811
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-04-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
=====================================================================
a) Name Mr R Simard
=== ======================== ===========================================
b) Position/status President, Pharma Supply Chain
=== ======================== ===========================================
c) Initial notification/ Initial notification
amendment
=== ======================== ===========================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== =====================================================================
a) Name GlaxoSmithKline plc
=== ======================== ===========================================
b) LEI 5493000HZTVUYLO1D793
=== ======================== ===========================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== =====================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ======================== ===========================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to
shareholders on 11 April 2019.
=== ======================== ===========================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 590.721
----------
=== ======================== ===========================================
d) Aggregated information n/a (single transaction)
Aggregated volume
Price
=== ======================== ===========================================
e) Date of the transaction 2019-04-15
=== ======================== ===========================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ======================== ===========================================
1. Details of PDMR/person closely associated with them
('PCA')
============================================================================
a) Name Mr P C Thomson
=== ====================== ====================================================
b) Position/status President, Global Affairs
=== ====================== ====================================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ============================================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================================
a) Description Ordinary shares of 25 pence each ('Ordinary
of the financial Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to shareholders
on 11 April 2019.
=== ====================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 706.619
----------
=== ====================== ====================================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ====================================================
e) Date of the 2019-04-15
transaction
=== ====================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
============================================================================
a) Name Mrs K Thomson
=== ====================== ====================================================
b) Position/status PCA of Mr P C Thomson (President, Global
Affairs)
=== ====================== ====================================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ============================================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================================
a) Description Ordinary shares of 25 pence each ('Ordinary
of the financial Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================================
b) Nature of the Acquisition of Ordinary Shares following
transaction the re-investment of dividends paid to shareholders
on 11 April 2019.
=== ====================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s) ----------
GBP15.5009 154.042
----------
=== ====================== ====================================================
d) Aggregated n/a (single transaction)
information
Aggregated
volume Price
=== ====================== ====================================================
e) Date of the 2019-04-15
transaction
=== ====================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHQQLFFKZFFBBX
(END) Dow Jones Newswires
April 16, 2019 12:14 ET (16:14 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024